Core Viewpoint - XuanZhu Biopharma (02575) has seen a significant stock price increase of over 8%, reaching approximately 28.46 HKD, which is nearly 150% higher than its IPO price of 11.6 HKD [1] Company Overview - XuanZhu Biopharma is an innovation-driven biopharmaceutical company based in China, actively developing over ten drug assets targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1] - The company has three drug assets that have received NDA approval, one drug project in the NDA registration stage, one in Phase III clinical trials, four in Phase I clinical trials, and five that have received IND approval [1] Fund Utilization - The net proceeds from the global offering amount to approximately 701 million HKD, with the following allocation plans: - About 45% will be used for the research and commercialization of core products (KBP-3571, XZP-3287, and XZP-3621) [1] - Approximately 14% will be allocated to the research of key products (KM602, KM501, XZP-7797, and XZP-6924) [1] - Around 11% will be directed towards the development of other candidate drugs (XZB-0004, XZP-5610, XZP-6019, and XZP-6877) [1] - About 20% will enhance commercialization and marketing capabilities, particularly through expanding sales and marketing teams [1] - Approximately 10% will be used for working capital and other general corporate purposes [1]
港股异动 | 轩竹生物(02575)尾盘涨超8% 较招股价涨近150% 公司拥超过十余种正在研发的药物管线